In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 2.02 million shares were traded. AMLX stock price reached its highest trading level at $6.52 during the session, while it also had its lowest trading level at $6.185.
Ratios:
Our analysis of AMLX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.05 and its Current Ratio is at 12.05. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on June 24, 2025, initiated with a Buy rating and assigned the stock a target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 31 ’25 when FRATES JAMES M sold 10,896 shares for $3.47 per share. The transaction valued at 37,806 led to the insider holds 290,988 shares of the business.
Bedrosian Camille L sold 12,425 shares of AMLX for $43,082 on Mar 31 ’25. The Chief Medical Officer now owns 194,375 shares after completing the transaction at $3.47 per share. On Mar 31 ’25, another insider, Mazzariello Gina, who serves as the Chief Legal Officer of the company, sold 9,192 shares for $3.48 each. As a result, the insider received 31,954 and left with 187,969 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 571394432 and an Enterprise Value of 368708352. Its current Enterprise Value per Revenue stands at -289.865 whereas that against EBITDA is -1.783.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.48, which has changed by 2.621469 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $7.27, while it has fallen to a 52-week low of $1.62. The 50-Day Moving Average of the stock is 22.83%, while the 200-Day Moving Average is calculated to be 48.94%.
Shares Statistics:
AMLX traded an average of 1.23M shares per day over the past three months and 2742770 shares per day over the past ten days. A total of 89.08M shares are outstanding, with a floating share count of 65.31M. Insiders hold about 26.74% of the company’s shares, while institutions hold 80.07% stake in the company. Shares short for AMLX as of 1749772800 were 4039910 with a Short Ratio of 3.30, compared to 1747267200 on 4972837. Therefore, it implies a Short% of Shares Outstanding of 4039910 and a Short% of Float of 5.0.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 5.0 analysts are actively evaluating the performance of Amylyx Pharmaceuticals Inc (AMLX) in the stock market.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.45 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.77 and -$1.98 for the fiscal current year, implying an average EPS of -$1.88. EPS for the following year is -$1.54, with 6.0 analysts recommending between -$0.95 and -$1.98.
